Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANA M ELOSEGUI

Allopathic & Osteopathic Physicians Family Medicine

NPI
1447221130
CMS profile
201750
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$3,842.28

182 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,782.28 181
Education $60.00 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 182 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANA M ELOSEGUI

NPI 1447221130 · CMS profile ID 201750

Allopathic & Osteopathic Physicians / Family Medicine

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 182 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447221130?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANA M ELOSEGUI, NPI 1447221130, CMS profile ID 201750. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 182 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447221130?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ANA M ELOSEGUI, NPI 1447221130, CMS profile ID 201750. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 182 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447221130?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ANA M ELOSEGUI, NPI 1447221130, CMS profile ID 201750, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 182 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1447221130?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

182 matching records · $3,842.28 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 182 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 182.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Exact Sciences Corporation $18.0508/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235283790 CMS
Bayer Healthcare Pharmaceuticals Inc. $31.1108/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225528376 CMS
Ardelyx, Inc. $11.4408/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247846451 CMS
Paratek Pharmaceuticals, Inc. $32.8408/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181743962 CMS
AstraZeneca Pharmaceuticals LP $18.4808/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206594978 CMS
AstraZeneca Pharmaceuticals LP $19.3508/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206743276 CMS
Lilly USA, LLC $19.5008/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186509071 CMS
Sumitomo Pharma America, Inc. $17.5008/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1176643741 CMS
Dexcom, Inc. $19.0008/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250468995 CMS
PFIZER INC. $24.4008/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229131496 CMS
SANOFI-AVENTIS U.S. LLC $22.8008/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233369422 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.5508/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222846631 CMS
ABBVIE INC. $17.4307/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201816297 CMS
Bayer Healthcare Pharmaceuticals Inc. $24.2507/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225528374 CMS
Lilly USA, LLC $17.2707/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186477373 CMS
Ardelyx, Inc. $15.3507/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247846449 CMS
Bayer Healthcare Pharmaceuticals Inc. $110.7907/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225528388 CMS
PFIZER INC. $22.8807/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229159203 CMS
AstraZeneca Pharmaceuticals LP $28.2007/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207281501 CMS
Novo Nordisk Inc $21.4707/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188335282 CMS
ABBVIE INC. $20.4707/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201816295 CMS
Astellas Pharma US Inc $11.2707/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238710782 CMS
Lilly USA, LLC $13.7807/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186468389 CMS
Paratek Pharmaceuticals, Inc. $16.0507/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181743960 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $23.2507/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231796975 CMS
Alkermes, Inc. $22.9607/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222490160 CMS
ABBVIE INC. $5.4107/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201816293 CMS
Amgen Inc. $21.9807/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228351732 CMS
Paratek Pharmaceuticals, Inc. $22.9907/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181743958 CMS
AstraZeneca Pharmaceuticals LP $13.8207/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207266562 CMS
Lilly USA, LLC $9.6006/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186509067 CMS
ABBVIE INC. $8.8506/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201816291 CMS
Bayer Healthcare Pharmaceuticals Inc. $8.1406/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225528360 CMS
ABBVIE INC. $15.3306/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201816289 CMS
Lilly USA, LLC $15.7706/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186505069 CMS
AstraZeneca Pharmaceuticals LP $33.5906/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206246412 CMS
AstraZeneca Pharmaceuticals LP $22.6606/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207124561 CMS
Paratek Pharmaceuticals, Inc. $15.0006/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181743956 CMS
Ardelyx, Inc. $18.1106/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247846445 CMS
Ardelyx, Inc. $4.6906/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247846447 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $24.3306/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231796970 CMS
Dexcom, Inc. $21.7606/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250468993 CMS
Ardelyx, Inc. $12.3906/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247846443 CMS
AstraZeneca Pharmaceuticals LP $24.2806/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206833033 CMS
Bayer Healthcare Pharmaceuticals Inc. $29.7806/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225528372 CMS
Novo Nordisk Inc $27.4906/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188620367 CMS
ABBVIE INC. $27.5006/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201816287 CMS
Novo Nordisk Inc $27.4006/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188143913 CMS
Dexcom, Inc. $18.0306/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250468991 CMS
Lilly USA, LLC $20.5605/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186509069 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,746.27 274
PY2020 $4,437.71 261
PY2021 $5,003.59 245
PY2022 $3,670.73 192
PY2023 $3,590.93 164
PY2024 $5,771.73 209
PY2025 $3,842.28 182

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,035,941.87 198
PY2024 Recipient $1,655.46 9
PY2024 Principal investigator $1,640,586.20 67
PY2023 Recipient $2,469.20 8
PY2023 Principal investigator $77,487.06 21
PY2022 Recipient $2,129.44 3
PY2022 Principal investigator $145,286.23 35
PY2021 Principal investigator $199,042.42 34
PY2020 Principal investigator $254,871.29 68
PY2019 Principal investigator $310,443.24 42

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

198 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $18,881.25 12/23/2025 Non-covered Recipient Entity
INTERSPOND LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192138199
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 12/17/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674426
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 12/17/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674428
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 12/17/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674430
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,262.75 12/15/2025 Non-covered Recipient Entity
Interspond LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220795417
Principal investigator 1 ModernaTX, Inc. $307.35 12/15/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968775
Principal investigator 1 ModernaTX, Inc. $122.94 12/10/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968777
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674414
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674416
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674418
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674420
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674422
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674424
Principal investigator 1 ModernaTX, Inc. $9,966.51 11/27/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968667
Principal investigator 1 ModernaTX, Inc. $15,754.97 11/27/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968711
Principal investigator 1 ModernaTX, Inc. $4,045.25 11/27/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968727
Principal investigator 1 ModernaTX, Inc. $103,515.72 11/27/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968765
Principal investigator 1 GlaxoSmithKline, LLC. $19,538.65 11/25/2025 Non-covered Recipient Entity
INTERSPOND LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192129340
Principal investigator 1 ModernaTX, Inc. $273.20 11/20/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968663
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,050.00 11/13/2025 Non-covered Recipient Entity
Interspond LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220795413
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,752.55 11/13/2025 Non-covered Recipient Entity
Interspond LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220795415
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674402
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674404
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674406
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674408
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674410
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674412
Principal investigator 1 ModernaTX, Inc. $648.57 10/30/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968695
Principal investigator 1 ModernaTX, Inc. $3,236.20 10/27/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968669
Principal investigator 1 ModernaTX, Inc. $15,700.58 10/27/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968671
Principal investigator 1 ModernaTX, Inc. $24,731.71 10/27/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968715
Principal investigator 1 GlaxoSmithKline, LLC. $6,196.85 10/17/2025 Non-covered Recipient Entity
INTERSPOND LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192129322
Principal investigator 1 GlaxoSmithKline, LLC. $21,960.20 10/02/2025 Non-covered Recipient Entity
INTERSPOND LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192129335
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674390
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674392
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674394
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674396
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674398
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674400
Principal investigator 1 ModernaTX, Inc. $14,920.99 09/29/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968691
Principal investigator 1 ModernaTX, Inc. $16,241.72 09/29/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968697
Principal investigator 1 ModernaTX, Inc. $7,281.45 09/29/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968767
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 09/24/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674380
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 09/24/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674382
Principal investigator 1 Boehringer Ingelheim International GmbH $442.20 09/24/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674384
Principal investigator 1 Boehringer Ingelheim International GmbH $15.66 09/24/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674386
Principal investigator 1 Boehringer Ingelheim International GmbH $11.04 09/24/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674388
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,104.00 09/23/2025 Non-covered Recipient Entity
Interspond LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220795411
Principal investigator 1 Genentech, Inc. $1,249.35 09/12/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211638674
Principal investigator 1 Genentech, Inc. $10,174.05 09/12/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211638678
Principal investigator 1 Genentech, Inc. $1,500.00 09/12/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211638682
Principal investigator 1 Genentech, Inc. $3,713.00 09/12/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211638686
Principal investigator 1 Genentech, Inc. $675.00 09/12/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211638690
Principal investigator 1 Genentech, Inc. $1,800.00 09/12/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211638694
Principal investigator 1 GlaxoSmithKline, LLC. $22,204.00 09/03/2025 Non-covered Recipient Entity
INTERSPOND LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192138193
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674348
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674350
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674352
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674354
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674356
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674374
Principal investigator 1 ModernaTX, Inc. $16,679.60 08/28/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968701
Principal investigator 1 ModernaTX, Inc. $7,281.45 08/28/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968705
Principal investigator 1 ModernaTX, Inc. $52,673.50 08/28/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968757
Principal investigator 1 ModernaTX, Inc. $38,758.65 08/28/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968769
Principal investigator 1 GlaxoSmithKline, LLC. $34,279.80 08/13/2025 Non-covered Recipient Entity
INTERSPOND LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192129310
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,479.55 08/08/2025 Non-covered Recipient Entity
Interspond LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220795409
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674338
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674340
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674342
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674344
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674346
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 08/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674368
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674372
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,050.00 08/01/2025 Non-covered Recipient Entity
Interspond LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220795407
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 07/28/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674376
Principal investigator 1 Boehringer Ingelheim International GmbH $5.22 07/28/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674378
Principal investigator 1 ModernaTX, Inc. $4,006.73 07/28/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968725
Principal investigator 1 ModernaTX, Inc. $369.13 07/28/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968741
Principal investigator 1 ModernaTX, Inc. $2,427.15 07/28/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968747
Principal investigator 1 ModernaTX, Inc. $13,695.11 07/28/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968761
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,330.00 07/22/2025 Non-covered Recipient Entity
Interspond LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220795405
Principal investigator 1 GlaxoSmithKline, LLC. $800.00 07/18/2025 Non-covered Recipient Entity
LENUS RESEARCH
A PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY IN ADOLESCENT AND ADULT FEMAL No dispute reported 06/30/2026 1192129350
Principal investigator 1 ModernaTX, Inc. $3,236.20 07/16/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968677
Principal investigator 1 ModernaTX, Inc. $21,778.67 07/16/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968709
Principal investigator 1 ModernaTX, Inc. $44,245.74 07/16/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968745
Principal investigator 1 ModernaTX, Inc. $11,440.03 07/16/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968773
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,000.00 07/10/2025 Non-covered Recipient Entity
Interspond LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220795403
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674358
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674360
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674362
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674364
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674366
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674370
Principal investigator 1 GlaxoSmithKline, LLC. $3,586.29 07/01/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 1192129346
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,977.85 06/27/2025 Non-covered Recipient Entity
Interspond LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220795401
Principal investigator 1 GlaxoSmithKline, LLC. $45,740.90 06/18/2025 Non-covered Recipient Entity
LENUS RESEARCH
A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON No dispute reported 06/30/2026 1192135939
Principal investigator 1 ModernaTX, Inc. $42,449.95 06/18/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968675
Principal investigator 1 ModernaTX, Inc. $43,192.27 06/18/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968731
Principal investigator 1 ModernaTX, Inc. $3,236.20 06/18/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968743
Principal investigator 1 ModernaTX, Inc. $15,428.63 06/18/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968751
Principal investigator 1 GlaxoSmithKline, LLC. $2,316.60 06/11/2025 Non-covered Recipient Entity
LENUS RESEARCH
A PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY IN ADOLESCENT AND ADULT FEMAL No dispute reported 06/30/2026 1192135908
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,866.60 06/05/2025 Non-covered Recipient Entity
Interspond LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220795399
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674326
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674328
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674330
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674332
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674334
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674336
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,050.00 05/28/2025 Non-covered Recipient Entity
Interspond LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220795395
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,000.00 05/28/2025 Non-covered Recipient Entity
Interspond LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220795397
Principal investigator 1 GlaxoSmithKline, LLC. $13,266.88 05/28/2025 Non-covered Recipient Entity
LENUS RESEARCH
A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON No dispute reported 06/30/2026 1192135922
Principal investigator 1 GlaxoSmithKline, LLC. $23,304.96 05/28/2025 Non-covered Recipient Entity
LENUS RESEARCH
A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON No dispute reported 06/30/2026 1192135928
Principal investigator 1 ModernaTX, Inc. $14,902.86 05/28/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968665
Principal investigator 1 ModernaTX, Inc. $6,472.40 05/28/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968679
Principal investigator 1 ModernaTX, Inc. $101,133.12 05/28/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968687
Principal investigator 1 ModernaTX, Inc. $54,631.24 05/28/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968763
Principal investigator 1 GlaxoSmithKline, LLC. $8,202.30 05/21/2025 Non-covered Recipient Entity
INTERSPOND LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192127221
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $38.00 05/07/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220797663
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,000.00 05/05/2025 Non-covered Recipient Entity
Interspond LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220795391
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,200.00 05/05/2025 Non-covered Recipient Entity
Interspond LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220795393
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674314
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674316
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674318
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674320
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674322
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674324
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $308.00 04/28/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220797661
Principal investigator 1 ModernaTX, Inc. $12,135.75 04/28/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968661
Principal investigator 1 ModernaTX, Inc. $14,902.86 04/28/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968673
Principal investigator 1 ModernaTX, Inc. $93,020.76 04/28/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968771
Principal investigator 1 GlaxoSmithKline, LLC. $11,871.20 04/23/2025 Non-covered Recipient Entity
INTERSPOND LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192129316
Principal investigator 1 GlaxoSmithKline, LLC. $29,420.04 04/18/2025 Non-covered Recipient Entity
LENUS RESEARCH
A PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY IN ADOLESCENT AND ADULT FEMAL No dispute reported 06/30/2026 1192135916
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,389.45 04/14/2025 Non-covered Recipient Entity
Interspond LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220795389
Principal investigator 1 GlaxoSmithKline, LLC. $14,712.65 04/02/2025 Non-covered Recipient Entity
INTERSPOND LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192129329
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674302
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674304
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674306
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674308
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674310
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674312
Principal investigator 1 ModernaTX, Inc. $56,846.02 03/24/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968693
Principal investigator 1 ModernaTX, Inc. $14,431.48 03/24/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968703
Principal investigator 1 ModernaTX, Inc. $64,560.60 03/24/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968721
Principal investigator 1 ModernaTX, Inc. $4,854.30 03/24/2025 Non-covered Recipient Entity
PIONEER CLINICAL STUDIES
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968729
Principal investigator 1 GlaxoSmithKline, LLC. $21,808.80 03/21/2025 Non-covered Recipient Entity
LENUS RESEARCH
A PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY IN ADOLESCENT AND ADULT FEMAL No dispute reported 06/30/2026 1192129358
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,751.65 03/18/2025 Non-covered Recipient Entity
Interspond LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220795387
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,050.00 03/13/2025 Non-covered Recipient Entity
Interspond LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220795383
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,000.00 03/13/2025 Non-covered Recipient Entity
Interspond LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220795385
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 03/07/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220797659
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674276
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674278
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674280
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674282
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674284
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674286
Principal investigator 1 ModernaTX, Inc. $8,931.32 02/27/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968683
Principal investigator 1 ModernaTX, Inc. $173,246.40 02/27/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968689
Principal investigator 1 ModernaTX, Inc. $15,573.67 02/27/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968699
Principal investigator 1 ModernaTX, Inc. $14,435.46 02/27/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968719
Principal investigator 1 ModernaTX, Inc. $4,355.91 02/27/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968737
Principal investigator 1 ModernaTX, Inc. $83,054.25 02/27/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968749
Principal investigator 1 ModernaTX, Inc. $53,106.30 02/27/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968753
Principal investigator 1 ModernaTX, Inc. $5,663.35 02/27/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968759
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 02/25/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674292
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 02/25/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674294
Principal investigator 1 Boehringer Ingelheim International GmbH $5.22 02/25/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674296
Principal investigator 1 Boehringer Ingelheim International GmbH $16.56 02/25/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674298
Principal investigator 1 GlaxoSmithKline, LLC. $7,695.68 02/05/2025 Non-covered Recipient Entity
LENUS RESEARCH
A PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY IN ADOLESCENT AND ADULT FEMAL No dispute reported 06/30/2026 1192135944
Principal investigator 1 GlaxoSmithKline, LLC. $38,182.32 02/03/2025 Non-covered Recipient Entity
LENUS RESEARCH
A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON No dispute reported 06/30/2026 1192135933
Principal investigator 1 GlaxoSmithKline, LLC. $10,239.10 02/03/2025 Non-covered Recipient Entity
INTERSPOND LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192138188
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674264
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674266
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674268
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674270
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674272
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674274
Principal investigator 1 Boehringer Ingelheim International GmbH $1.55 01/27/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674288
Principal investigator 1 Boehringer Ingelheim International GmbH $1.45 01/27/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674290
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,884.30 01/27/2025 Non-covered Recipient Entity
Interspond LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220795381
Principal investigator 1 ModernaTX, Inc. $809.05 01/27/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968659
Principal investigator 1 ModernaTX, Inc. $46,889.43 01/27/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968681
Principal investigator 1 ModernaTX, Inc. $7,034.44 01/27/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968685
Principal investigator 1 ModernaTX, Inc. $23,949.90 01/27/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968707
Principal investigator 1 ModernaTX, Inc. $43,559.10 01/27/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968713
Principal investigator 1 ModernaTX, Inc. $6,492.33 01/27/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968733
Principal investigator 1 ModernaTX, Inc. $44,664.73 01/27/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968735
Principal investigator 1 ModernaTX, Inc. $37,536.72 01/27/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968755
Principal investigator 1 ModernaTX, Inc. $81.96 01/24/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968717
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,967.30 01/20/2025 Non-covered Recipient Entity
Interspond LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220795379
Principal investigator 1 ModernaTX, Inc. $95.62 01/16/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968739
Principal investigator 1 ModernaTX, Inc. $75.13 01/08/2025 Non-covered Recipient Entity
Pioneer Clinical Studies
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968723
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674254
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674256
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674258
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674260
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674262
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Lenus Research And Medical Group
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220674300